samedan logo
 
 
 
spacer
home > ebr > autumn 2002 > biotech investor relations - weathering the storm
PUBLICATIONS
European Biopharmaceutical Review

Biotech Investor Relations - Weathering the Storm

"The drug sector is out of favour...we have had 12 profits warnings in the pharma sector since January 2001 compared with two between 1990 and 2000. This is the worst time ever for pharma and it has impacted the biotech sector." Are these really the worst market conditions yet? Many think they are and it is certainly true that 2002 has so far been a roller coaster ride for investors in the biotech industry. Can companies attract investor support despite the doom and gloom? What should companies be doing to maximise the value of their shares? The biotech sector is suffering from the excesses of 2000 when over US$37 billion (versus US$16 billion in 2001) was raised, as well as from the poor broad market conditions. The market malaise reflects an uncertain outlook for equities in general, especially for high growth/risk sectors such as early stage biotechnology and technology-related stocks.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Mary Clark, Managing Director of Life Sciences Consulting at Thomson Financial

Mary Clark is Managing Director, Life Sciences Consulting at Thomson Financial. She specialises in building proactive investor relations programmes for life sciences companies at all stages of development, ranging from pre-IPO initiatives to expanding the reach of established multinational corporations.
Prior to joining Thomson Financial, Mary was Global Director of Corporate Communications at BTG plc, where she had overall responsibility for its investor relations, PR and media functions.

spacer
Mary Clark
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera wins Pharmapack Award in Connected Devices and Wearables category with its body injector platform Symbioze

Symbioze, the smart, high volume and sustainable on-body injector platform developed by Nemera, wins the ‘Connected Devices and Wearables’ Award at Pharmapack 2021 On October 12th, during the Pharmapack Awards Ceremony, a team of industry experts awarded Symbioze, Nemera’s large-volume on-body injector, with the Pharmapack Award in the “Connected Devices and Wearables” category.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

Aigenpulse

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement